AIM IMMUNOTECH INC. Finite-lived Intangible Assets Acquired
AIM IMMUNOTECH INC. (AIM) reported Finite-lived Intangible Assets Acquired of $147.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Goodwill and Other
us-gaap:FinitelivedIntangibleAssetsAcquired1 · last filed 2026-08-07
- AIM IMMUNOTECH INC. finite-lived intangible assets acquired for the quarter ending 2026-06-30 was $112.00K, a 50.66% decline year-over-year.
- AIM IMMUNOTECH INC. finite-lived intangible assets acquired for the quarter ending 2026-03-31 was $35.00K, a 37.50% decline year-over-year.
- AIM IMMUNOTECH INC. finite-lived intangible assets acquired for the quarter ending 2025-12-31 was $95.00K, a 20.17% decline year-over-year.
- AIM IMMUNOTECH INC. finite-lived intangible assets acquired for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- AIM IMMUNOTECH INC. finite-lived intangible assets acquired for fiscal 2025 was $378.00K, a 29.74% decline from fiscal 2024.
- AIM IMMUNOTECH INC. finite-lived intangible assets acquired for fiscal 2024 was $538.00K, a 8.03% decline from fiscal 2023.
- AIM IMMUNOTECH INC. finite-lived intangible assets acquired for fiscal 2023 was $585.00K.
- AIM IMMUNOTECH INC. finite-lived intangible assets acquired for fiscal 2021 was $592.00K, a 3.32% increase from fiscal 2020.
| Period end | Finite-lived Intangible Assets Acquired 3 month | Finite-lived Intangible Assets Acquired 6 month | Finite-lived Intangible Assets Acquired 9 month | Finite-lived Intangible Assets Acquired 12 month |
|---|---|---|---|---|
| 2026-06-30 | $112.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $147.00K 10-Q · filed 2026-08-07 | $242.00K derived: sum of 3 quarters · filed 2026-08-07 | $242.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $35.00K 10-Q · filed 2026-05-15 | $130.00K derived: sum of 2 quarters · filed 2026-05-15 | $130.00K derived: sum of 3 quarters · filed 2026-05-15 | $357.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $95.00K derived: sum of 2 quarters · filed 2026-03-27 | $322.00K derived: sum of 3 quarters · filed 2026-03-27 | $378.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $227.00K derived: sum of 2 quarters · filed 2025-11-17 | $283.00K 10-Q · filed 2025-11-17 | $402.00K derived: sum of 4 quarters · filed 2025-11-17 |
| 2025-06-30 | $227.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $283.00K 10-Q · filed 2025-08-14 | $402.00K derived: sum of 3 quarters · filed 2025-08-14 | $539.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | $56.00K 10-Q · filed 2025-05-15 | $175.00K derived: sum of 2 quarters · filed 2025-05-15 | $312.00K derived: sum of 3 quarters · filed 2025-05-15 | $544.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $256.00K derived: sum of 2 quarters · filed 2025-03-27 | $488.00K derived: sum of 3 quarters · filed 2025-03-27 | $538.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $137.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $369.00K derived: sum of 2 quarters · filed 2024-11-14 | $419.00K 10-Q · filed 2024-11-14 | $627.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | $232.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $282.00K 10-Q · filed 2024-08-14 | $490.00K derived: sum of 3 quarters · filed 2024-08-14 | $657.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | $50.00K 10-Q · filed 2024-05-15 | $258.00K derived: sum of 2 quarters · filed 2024-05-15 | $425.00K derived: sum of 3 quarters · filed 2024-05-15 | |
| 2023-12-31 | $208.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $375.00K derived: sum of 2 quarters · filed 2024-04-01 | $585.00K 10-K · filed 2024-04-01 | |
| 2023-09-30 | $167.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $377.00K 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $210.00K 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $279.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2023-08-14 | $299.00K derived: sum of 2 quarters · filed 2023-08-14 | $342.00K derived: sum of 3 quarters · filed 2023-08-14 | $375.00K 10-Q · filed 2023-08-14 |
| 2022-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $63.00K derived: sum of 2 quarters · filed 2022-11-14 | $96.00K 10-Q · filed 2022-11-14 | $244.00K derived: sum of 4 quarters · filed 2023-03-31 |
| 2022-06-30 | $43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $76.00K 10-Q · filed 2022-08-15 | $224.00K derived: sum of 3 quarters · filed 2023-03-31 | $303.00K derived: sum of 4 quarters · filed 2023-03-31 |
| 2022-03-31 | $33.00K 10-Q · filed 2022-05-13 | $181.00K derived: sum of 2 quarters · filed 2023-03-31 | $260.00K derived: sum of 3 quarters · filed 2023-03-31 | $260.00K derived: sum of 4 quarters · filed 2023-03-31 |
| 2021-12-31 | $148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $227.00K derived: sum of 2 quarters · filed 2023-03-31 | $227.00K derived: sum of 3 quarters · filed 2023-03-31 | $592.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $79.00K derived: sum of 2 quarters · filed 2021-11-15 | $444.00K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $365.00K 10-Q · filed 2021-08-16 | ||
| 2021-03-31 | $365.00K 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $573.00K 10-K · filed 2022-03-31 | |||
| 2019-12-31 | $297.00K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |